Document is current

Article History

Accepted: 21 November 2024

First Online: 6 December 2024

Declarations

:

: This work was supported by Bristol Myers Squibb. Bristol Myers Squibb provided funding for study and medical writing support. Publication of the study was not contingent on Bristol Myers Squibb’s approval or censorship of the manuscript.

: Kyna Gooden, Derek Tang, and Samantha Slaff report employment by and stock ownership in Bristol Myers Squibb. Yu-Hsuan Shih reports travel support and employment from Bristol Myers Squibb, stock ownership in Novartis, and support for study materials and medical writing from the study team from University of Utah. Nathorn Chaiyakunapruk reports research funding from Bristol Myers Squibb. Chia Jie Tan is an Editorial Board Member of PharmacoEconomics. He was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. All other authors have stated that they do not have any conflicts of interest regarding the content of this article.

: The University of Utah Institutional Review Board (IRB) approved this study (IRB-00147477) to be exempt from human subject review.

: Not applicable.

: Not applicable.

: For the Bristol Myers Squibb data sharing policy, see .

: Not applicable.

: All authors conceptualized and designed the study and critically revised the manuscript for important intellectual content. Syeed, Tan, Ngorsuraches, and Chaiyakunapruk acquired the data; Syeed, Tan, Gooden, Ngorsuraches, and Chaiyakunapruk analyzed and interpreted the data; Syeed, Tan, Ngorsuraches, and Chaiyakunapruk drafted the manuscript; Syeed, Tan, and Ngorsuraches performed statistical analysis and provision of study materials; Chaiyakunapruk acquired funding; Syeed, Tan, and Ngorsuraches provided administrative, technical, or logistic support; and Gooden, Tang, Ngorsuraches, and Chaiyakunapruk provided supervision. All authors read and approved the final manuscript.